Intranasal fentanyl spray for breakthrough cancer pain: An innovative approach to the unmet needs
European Journal of Pain Supplements · 2010
DOI: 10.1016/j.eujps.2010.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pain Supplements, 2010. Verfasst von Hans G. Kress. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
The treatment of breakthrough pain (BTP) in cancer patients is often sub‐optimal. Normal‐release oral opioid formulations have a slow onset of action, such that the episode of pain has often spontaneously subsided by the time the opioid starts to work. Other oral formulations, such as oral transmucosal fentanyl citrate (OTFC), may be associated with administration problems in many cancer patients who have salivary gland dysfunction or mucositis. Thus, there is the need for a treatment that matches a typical BTP episode and that is easy to use. Intranasal fentanyl spray (INFS) has been developed as a new route of administration with a fast onset of action. INFS has been investigated in four key clinical studies involving cancer patients with BTP. Pharmacokinetic analysis has shown a dose response for maximal plasma concentrations ( C max ) of fentanyl and a short venous time to maximum plasma concentration ( T max ). A dose‐ranging efficacy study demonstrated a significant improvement in pain intensity difference (PID) over placebo from as early as 10min post‐administration. A later titrated‐dose efficacy study supported these findings. In a head‐to‐head comparative trial between INFS and OTFC, significantly more patients achieved a faster onset of ‘meaningful’ pain relief with INFS than with OTFC, with INFS producing a significantly greater PID as early as 5min post‐dosing. Furthermore, a significantly higher proportion of patients preferred INFS over OTFC. In all clinical studies, including a 10‐month follow‐up, INFS was well tolerated. INFS should be considered a significant advance for the management of BTP.
Zitieren
APA
Kress, H. G. (2010). Intranasal fentanyl spray for breakthrough cancer pain: An innovative approach to the unmet needs. European Journal of Pain Supplements. https://doi.org/10.1016/j.eujps.2010.06.005
Vancouver
Kress HG. Intranasal fentanyl spray for breakthrough cancer pain: An innovative approach to the unmet needs. European Journal of Pain Supplements. 2010. doi:10.1016/j.eujps.2010.06.005
BibTeX
@article{Kress2010,
author = {Kress, Hans G.},
title = {Intranasal fentanyl spray for breakthrough cancer pain: An innovative approach to the unmet needs},
journal = {European Journal of Pain Supplements},
year = {2010},
doi = {10.1016/j.eujps.2010.06.005}
}
EUVIMED